Johnson & Johnson (JNJ) is seeing good growth from its Medical Technology division as people are opting for elective procedures again.
Johnson & Johnson (JNJ) is set to spin off its Consumer Brands division this week, which could make J&J a faster growing company.
Johnson & Johnson (JNJ) delivered solid profit growth of 10% last qtr even though sales fell because of the strong US dollar.
Currency exchange is expected to cut Johnson & Johnson’s (JNJ) profits (EPS) from $10.73 to $10.05 this year. Strong US dollar.
The combination of inflation and a strong US dollar hurt Johnson & Johnson’s (JNJ) profits last qtr and reduced estimates for the year.
Johnson & Johnson (JNJ) begins to see the benefits of increased demand for general and advanced surgery post-Covid.
Johnson & Johnson (JNJ) is a true value stock with a P/E of only 16 and seems like a solid selection in this rocky stock market.
Johnson & Johnson (JNJ) is planning to split into two companies, which might end up making JNJ stock grow faster than it has.
Analysts have high expectations for Johnson & Johnson (JNJ), as the estimated growth rate has been accelerating lately.
Johnson & Johnson (JNJ) is growing profits at double-digit rates again. Our 2021 Fair Value in this $165 stock is $198.
Johnson & Johnson (JNJ) had revenue suffer due to people postponing elective surgeries. Now, things are looking up.
Johnson & Johnson (JNJ) stock has nice upside potential, even if its (potential) COVID-19 vaccine delivers profits.
Johnson & Johnson (JNJ) has a pipeline of new drugs including a nasal spray for depression and COVID-19 vaccine candidate.
J&J (JNJ) is optimistic it can have a COVID-19 vaccine by early 2021. But slow medical device sales are hurting profits now.
Johnson & Johnson (JNJ) was overcome by legislation fears last year. But now the stock is back to All-Time highs.
Johnson & Johnson (JNJ) is in the news due to talcum powder and opioid litigation, and this seems to be holding JNJ down.
Johnson & Johnson (JNJ) had profit growth of 15% last qtr on 11% sales growth. Both figures are impressive. With the stock still down on the year, it’s a good time to buy.
Johnson & Johnson (JNJ) just took sales growth and profit growth to another level — the double digit level. And with a P/E of 18 the stock is quite reasonable.
Johnson & Johnson (JNJ) has grown profits 6% per year the past decade, but its possible the company could grow profits 9% for the third year in a row.
Johnson & Johnson (JNJ) is one of THE safest stocks in the world, but investors shouldn’t expect double-digit growth from this high quality company.
Johnson & Johnson (JNJ) is having an outstanding year, and also has up to 10 Billion dollar drugs in its pipeline to boost future profits.